Share on twitter
Share on LinkedIn
Share on Facebook
Email to a friend
Print page
Read and download the new FSRH Service Standards for Resuscitation in Sexual and Reproductive Healthcare Services, published in December 2022.
You are welcome to download our freely available Guideline documents by clicking on the document title above.
This document is up-to-date
1 CPD credit can be claimed for answering the questions.
This resource is available to members/candidates of FSRH.
This document is up-to-date
This guideline provides evidence-based recommendations and good practice points for health professionals on the use of progestogen-only contraceptive pills. It is intended for any health care professional or health service providing contraceptive care in the UK. Also available in digital format on the BMJ website: FSRH Guideline (August 2022) Progestogen-only Pills. BMJ Sexual & Reproductive Health 2022; 48:Suppl 1 .
You are welcome to download our freely available Guideline documents by clicking on the document title above.
This document is up-to-date
This summary has been written as a quick reference guide to help busy clinicians to give clear, safe advice on progestogen-only contraceptive pills. Please refer to the full 2022 FSRH Progestogen-only Pills Clinical Guideline for further information and supporting evidence for this advice. This document is written for FSRH members and requires you to log in to access it.
This resource is available to members/candidates of FSRH.
This document is up-to-date
This guideline provides evidence-based recommendations and good practice points for health professionals on the use of progestogen-only contraceptive pills. It is intended for any healthcare professional or health service providing contraceptive care in the UK. In this version of the POP Guideline, the supporting evidence for the recommendations has been removed from the main text and located in an appendix for ease of reading. This document is available to FSRH members and candidates only.
This resource is available to members/candidates of FSRH.
This document is up-to-date
This FSRH Statement responses to a recently published cohort study, which used information from Finnish databases, assessed incidence of confirmed venous thromboembolic (VTE) events in 2018/19 amongst the roughly 300,000 Finnish people aged 15-49 who were using hormonal contraception (HC) in 2017 (identified from the prescribing database) and age-matched controls who were not using hormonal contraception.
You are welcome to download our freely available Guideline documents by clicking on the document title above.
This document is up-to-date
This summary has been written as a quick reference guide to help busy clinicians to give clear, safe advice on combined hormonal contraception (CHC). Please refer to the full 2018 FSRH CHC Clinical Guideline for further information and evidence for this advice. This document is written for FSRH members and requires you to log in to access it.
This resource is available to members/candidates of FSRH.
This document is up-to-date
This summary has been written as a quick reference guide to help busy clinicians to give clear, safe advice on Progestogen-only Implant. Please refer to the full 2018 FSRH Progestogen-only Implant Clinical Guideline for further information and evidence for this advice.
This resource is available to members/candidates of FSRH.
This document is up-to-date
This quick guide advises on effective starting or switching between contraceptive methods to reduce the risk of unplanned pregnancy. It summarises information from existing FSRH guidance documents. This guide should be used in conjunction with clinical judgment in individual situations. Amended in March 2021.
This resource is available to members/candidates of FSRH.
This document is up-to-date
FSRH Clinical Guideline: Contraception After Pregnancy Executive Summary (January 2017)
You are welcome to download our freely available Guideline documents by clicking on the document title above.
Please read this guidance document in conjunction with any relevant clinical statements for this topic.
